1. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells.
- Author
-
Morgan ME, Flierman R, van Duivenvoorde LM, Witteveen HJ, van Ewijk W, van Laar JM, de Vries RR, and Toes RE
- Subjects
- Animals, Arthritis, Experimental immunology, Arthritis, Experimental pathology, Bone Marrow Transplantation, CD4 Antigens biosynthesis, DNA-Binding Proteins biosynthesis, DNA-Binding Proteins genetics, Disease Models, Animal, Forkhead Transcription Factors, Immunosuppression Therapy, Mice, RNA, Messenger metabolism, Receptors, Interleukin-2 biosynthesis, Reverse Transcriptase Polymerase Chain Reaction, Synovial Membrane metabolism, Synovial Membrane pathology, T-Lymphocytes metabolism, T-Lymphocytes transplantation, Adoptive Transfer, Arthritis, Experimental therapy, CD4 Antigens immunology, Immunotherapy, Receptors, Interleukin-2 immunology, T-Lymphocytes immunology
- Abstract
Objective: Regulatory T cells play an important role in the prevention of autoimmunity and have been shown to be effective in the treatment of experimental colitis, a T cell-mediated and organ-specific disease. We previously demonstrated that intrinsic CD25+ regulatory T cells modulate the severity of collagen-induced arthritis (CIA), which, in contrast to colitis, is a systemic antibody-mediated disease and an accepted model of rheumatoid arthritis. We undertook this study to determine whether regulatory T cells have the potential to be used therapeutically in arthritis., Methods: We transferred CD4+,CD25+ T cells into mice exhibiting arthritis symptoms, both immunocompetent mice and mice subjected to lethal irradiation and rescued with syngeneic bone marrow transplantation., Results: A single transfer of regulatory T cells markedly slowed disease progression, which could not be attributed to losses of systemic type II collagen-specific T and B cell responses, since these remained unchanged after adoptive transfer. However, regulatory T cells could be found in the inflamed synovium soon after transfer, indicating that regulation may occur locally in the joint., Conclusion: Our data indicate that CD25+ regulatory T cells can be used for the treatment of systemic, antibody-mediated autoimmune diseases, such as CIA.
- Published
- 2005
- Full Text
- View/download PDF